BRD9 and posterior cortical atrophy: Notably, pharmacological and genetic suppression of BRD9 results in defective and inactivated glycolysis-PPP, impaired antioxidant activity, defective mitochondrial OXPHOS, pronounced DNA damage, and PCa regression.